Tag: rates

Not for distribution to United States newswire services or for dissemination in the United States

BOCA RATON, FL, July 10, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), announced today the purchase of 153,225 Solana (“SOL”) at an average purchase price of $154.85 and valued at approximately $23.72 million. Following this transaction, DeFi Dev Corp. now holds approximately 846,630 SOL and SOL equivalents, including staking rewards, making the Company the largest Solana treasury company, by both total holdings and market capitalization.

FREMONT, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, today announced that production shipments of its newest electric vehicle (EV) charger, the IQ^® EV Charger 2, have expanded across Europe to now include Greece, Romania, Ireland, and Poland. The IQ EV Charger 2 is a smart charger designed to work seamlessly with Enphase solar and battery systems or as a powerful standalone charger. Additionally, in France, the IQ EV Charger 2 has received one of the country’s highest quality standards, the E.V. READY certification, and can now integrate with the “Linky” meter to enable dynamic load balancing for standalone charger installations.

NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), will present new findings at the upcoming Alzheimer's Association International Conference (AAIC®) 2025 in Toronto. The presentations include a cost savings analysis of the use of pTau217 as a screening tool in Acumen’s Phase 2 ALTITUDE-AD trial of sabirnetug as well as a nonclinical study evaluating the relative selectivity of sabirnetug to targeting AβOs versus Aβ monomers. The conference will be held July 27-31, 2025, both in-person and online.

Targeted Maximum 2025 Production Rate Has Been Achieved After Less Than 6 Weeks of Production

U.S. Developer Vows Vigorous Litigation & Project Completion
Click for Assets